CA
ALNY icon

Centerpoint Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Centerpoint Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed – – 425
2023
Q3 		$0 Hold
2
– – ﹤0.01% 557
2023
Q2 		$0 Hold
2
– – ﹤0.01% 557
2023
Q1 		$0 Buy
+2
New +$420 ﹤0.01% 548

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Centerpoint Advisors's ALNY Position: Q4 2023 in Review

Centerpoint Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 2 shares.

Centerpoint Advisors first reported a position in ALNY in Q1 2023 and held it in 3 quarters. The position peaked at $0 in Q3 2023. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Centerpoint Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centerpoint Advisors sold 2 Alnylam Pharmaceuticals shares in Q4 2023.
  • Centerpoint Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Centerpoint Advisors's Alnylam Pharmaceuticals position peaked at $0 in Q3 2023.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Centerpoint Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.